Traders Buy High Volume of Eli Lilly and Company Call Options (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY) saw some unusual options trading activity on Wednesday. Stock traders bought 50,761 call options on the stock. This represents an increase of approximately 30% compared to the average volume of 39,145 call options.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approved Lilly’s oral GLP‑1 weight‑loss pill Foundayo (orforglipron), broadening Lilly’s obesity portfolio with a convenient, scalable product and immediate commercial rollout via LillyDirect. Lilly’s weight-loss pill wins US approval — Reuters
• Positive Sentiment: Lilly agreed to acquire Centessa Pharmaceuticals (deal up to ~$7.8B), adding orexin‑2 (OX2R) sleep‑wake candidates and diversifying beyond GLP‑1 into neuroscience — a strategic revenue‑diversification move. Eli Lilly to buy Centessa Pharma in $6.3 billion deal — Reuters
• Positive Sentiment: Lilly expanded its AI drug‑discovery push (multi‑billion dollar program) to accelerate pipeline creation — supports long‑term R&D productivity and the company’s premium valuation narrative. Eli Lilly bets on AI drugs in $2.75B deal — Yahoo Finance
• Positive Sentiment: Analyst commentary highlights Lilly’s strong earnings‑surprise history and a setup that could support another beat in coming quarters, reinforcing investor confidence in cash‑flow durability. Will Lilly beat estimates again? — Zacks
• Neutral Sentiment: Market commentators and TV personalities (e.g., Jim Cramer) are featuring Lilly in daily shows, increasing retail attention but with mixed short‑term impact. Cramer’s Mad Dash: Eli Lilly — YouTube
• Negative Sentiment: Lilly’s CEO publicly opposes a White House push to codify “Most Favored Nations” drug‑pricing deals into law — signals added regulatory/policy risk that could pressure margins or pricing dynamics. Eli Lilly opposes push to pass Trump’s MFN drug pricing deals into law — CNBC
• Negative Sentiment: Rival Novo Nordisk rolled out subscription pricing for Wegovy (and its pill), undercutting cash‑pay pricing and intensifying competition in the GLP‑1 market — a margin and market‑share headwind to monitor. Novo launches Wegovy subscription pricing — Blockonomi
• Negative Sentiment: Guggenheim has trimmed expectations for Lilly’s stock price, signaling some sell‑side caution on valuation even as fundamentals remain strong. Guggenheim lowers expectations for LLY — American Banking News

Institutional Investors Weigh In On Eli Lilly and Company

A number of large investors have recently modified their holdings of LLY. Maryland Capital Advisors Inc. purchased a new position in Eli Lilly and Company in the 4th quarter worth approximately $25,000. Osbon Capital Management LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $25,000. Basso Capital Management L.P. acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $30,000. Miller Global Investments LLC purchased a new position in Eli Lilly and Company during the fourth quarter worth approximately $33,000. Finally, E Fund Management Hong Kong Co. Ltd. boosted its stake in Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after buying an additional 24 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

NYSE:LLY traded up $37.17 during trading hours on Wednesday, hitting $956.94. 4,027,705 shares of the stock were exchanged, compared to its average volume of 3,184,934. The firm’s fifty day moving average price is $1,001.75 and its 200 day moving average price is $966.95. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95. The company has a market cap of $904.13 billion, a P/E ratio of 41.75, a P/E/G ratio of 1.03 and a beta of 0.40. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. During the same quarter last year, the business posted $5.32 earnings per share. The business’s quarterly revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

LLY has been the subject of a number of analyst reports. CICC Research upped their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 11th. Royal Bank Of Canada assumed coverage on Eli Lilly and Company in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $1,250.00 price target for the company. Zacks Research cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Berenberg Bank raised their price objective on Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a report on Thursday, February 19th. Finally, Guggenheim cut their price objective on Eli Lilly and Company from $1,168.00 to $1,163.00 and set a “buy” rating for the company in a research report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,221.26.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.